Viracta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results. Also, the Company Announced Its Phase 2 NAVAL-1 Trial Results and Will Begin a Randomized Controlled Trial (RCT).
Viracta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results. Also, the Company Announced Its Phase 2 NAVAL-1 Trial Results and Will Begin a Randomized Controlled Trial (RCT).
Viracta Therapeutics股票上漲，因爲該公司報告了超預期的Q2每股收益結果。此外，該公司宣佈了其2期NAVAL-1試驗結果，並將開始一項隨機對照試驗（RCT）。
Viracta Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results. Also, the Company Announced Its Phase 2 NAVAL-1 Trial Results and Will Begin a Randomized Controlled Trial (RCT).
Viracta Therapeutics股票上漲，因爲該公司報告了超預期的Q2每股收益結果。此外，該公司宣佈了其2期NAVAL-1試驗結果，並將開始一項隨機對照試驗（RCT）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間